Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
Status:
Completed
Trial end date:
2018-04-20
Target enrollment:
Participant gender:
Summary
To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced
or metastatic breast cancer, who have failed >/= 1 but < 5 prior lines of chemotherapy;
locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy
failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with
docetaxel (75 mg/m2) + plinabulin (20 mg/m^2) versus docetaxel (75 mg/m2) + pegfilgrastim (6
mg).